4Basebio PLC
LSE:4BB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (1.1), the stock would be worth GBX-111.08 (122% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.1 | GBX505 |
0%
|
| Industry Average | 1.1 | GBX-111.08 |
-122%
|
| Country Average | 0.2 | GBX-20.46 |
-104%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
4
|
4Basebio PLC
LSE:4BB
|
78.3m GBP | -5.1 | -5.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 23.5 | 87.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 21.8 | 22.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 24 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 34 | 27.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 19.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 35.6 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
4Basebio PLC
Glance View
4basebio Plc develops gene therapy technologies and solutions. The firm is engaged in developing next generation gene therapy technologies and solutions. The firm is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The firm focuses to manufacture and supply synthetic DNA for research, therapeutic and pharmacological use. Its TruePrime DNA amplification technology is a primer free DNA amplification method using enzymes. Its Hermes is a non-viral delivery platform that can be used to deliver various payloads, ranging from DNA to small interfering ribonucleic acid (siRNA), as well as protein cargoes. The company also offers a messenger ribonucleic acid (mRNA) production service from the DNA template it makes. The company offers a range of services including production of synthetic DNA and RNA payloads, design and assembly of payloads in nanoparticles.
